Futura Medical plc (FAMDF)
USD 0.12
(26.32%)
USD 0.12
(26.32%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -7.71 Million GBP | -91.6% |
| 2022 | -4.02 Million GBP | 61.19% |
| 2021 | -10.37 Million GBP | -918.32% |
| 2020 | -1.01 Million GBP | 59.43% |
| 2019 | -2.51 Million GBP | 72.59% |
| 2018 | -9.15 Million GBP | -9.51% |
| 2017 | -8.36 Million GBP | 32.3% |
| 2016 | -12.35 Million GBP | -194.94% |
| 2015 | -4.18 Million GBP | 55.87% |
| 2014 | -9.49 Million GBP | -858.22% |
| 2013 | -990.56 Thousand GBP | 64.84% |
| 2012 | -2.81 Million GBP | -9.1% |
| 2011 | -2.58 Million GBP | -212.97% |
| 2010 | -825 Thousand GBP | 53.88% |
| 2009 | -1.78 Million GBP | -128.77% |
| 2008 | -782 Thousand GBP | 70.36% |
| 2007 | -2.63 Million GBP | 3.76% |
| 2006 | -2.74 Million GBP | -51.52% |
| 2005 | -1.8 Million GBP | 50.74% |
| 2004 | -3.67 Million GBP | -52.87% |
| 2003 | -2.4 Million GBP | -58.97% |
| 2002 | -1.51 Million GBP | 26.04% |
| 2001 | -2.04 Million GBP | -962.03% |
| 2000 | 237 Thousand GBP | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -3.92 Million GBP | 49.18% |
| 2024 Q2 | -3.92 Million GBP | 0.0% |
| 2023 Q3 | -7.71 Million GBP | 1.59% |
| 2023 Q1 | -7.83 Million GBP | -94.7% |
| 2023 FY | -7.71 Million GBP | -91.6% |
| 2023 Q2 | -7.83 Million GBP | 0.0% |
| 2023 Q4 | -7.71 Million GBP | 0.0% |
| 2022 Q3 | -4.02 Million GBP | 39.69% |
| 2022 Q4 | -4.02 Million GBP | 0.0% |
| 2022 FY | -4.02 Million GBP | 61.19% |
| 2022 Q1 | -6.67 Million GBP | 35.64% |
| 2022 Q2 | -6.67 Million GBP | 0.0% |
| 2021 Q3 | -10.37 Million GBP | 18.72% |
| 2021 Q2 | -12.76 Million GBP | 0.0% |
| 2021 Q1 | -12.76 Million GBP | -1152.91% |
| 2021 FY | -10.37 Million GBP | -918.32% |
| 2021 Q4 | -10.37 Million GBP | 0.0% |
| 2020 Q2 | -2.61 Million GBP | 0.0% |
| 2020 FY | -1.01 Million GBP | 59.43% |
| 2020 Q1 | -2.61 Million GBP | -4.17% |
| 2020 Q3 | -1.01 Million GBP | 61.05% |
| 2020 Q4 | -1.01 Million GBP | 0.0% |
| 2019 Q2 | -5.62 Million GBP | 0.0% |
| 2019 Q1 | -5.62 Million GBP | 38.56% |
| 2019 FY | -2.51 Million GBP | 72.59% |
| 2019 Q3 | -2.51 Million GBP | 55.38% |
| 2019 Q4 | -2.51 Million GBP | 0.0% |
| 2018 Q2 | -6.02 Million GBP | 0.0% |
| 2018 Q3 | -9.15 Million GBP | -51.99% |
| 2018 FY | -9.15 Million GBP | -9.51% |
| 2018 Q1 | -6.02 Million GBP | 27.95% |
| 2018 Q4 | -9.15 Million GBP | 0.0% |
| 2017 Q2 | -10.12 Million GBP | 0.0% |
| 2017 Q1 | -10.12 Million GBP | 18.06% |
| 2017 FY | -8.36 Million GBP | 32.3% |
| 2017 Q4 | -8.36 Million GBP | 0.0% |
| 2017 Q3 | -8.36 Million GBP | 17.39% |
| 2016 Q2 | -2.9 Million GBP | 0.0% |
| 2016 FY | -12.35 Million GBP | -194.94% |
| 2016 Q4 | -12.35 Million GBP | 0.0% |
| 2016 Q3 | -12.35 Million GBP | -325.93% |
| 2016 Q1 | -2.9 Million GBP | 30.75% |
| 2015 Q1 | -7.23 Million GBP | 23.78% |
| 2015 Q4 | -4.18 Million GBP | 0.0% |
| 2015 Q3 | -4.18 Million GBP | 42.11% |
| 2015 Q2 | -7.23 Million GBP | 0.0% |
| 2015 FY | -4.18 Million GBP | 55.87% |
| 2014 Q1 | -11.21 Million GBP | -1032.17% |
| 2014 Q2 | -11.21 Million GBP | 0.0% |
| 2014 Q3 | -9.49 Million GBP | 15.36% |
| 2014 FY | -9.49 Million GBP | -858.22% |
| 2014 Q4 | -9.49 Million GBP | 0.0% |
| 2013 Q1 | -2.11 Million GBP | 24.88% |
| 2013 FY | -990.56 Thousand GBP | 64.84% |
| 2013 Q3 | -990.56 Thousand GBP | 53.19% |
| 2013 Q2 | -2.11 Million GBP | 0.0% |
| 2013 Q4 | -990.56 Thousand GBP | 0.0% |
| 2012 Q4 | -2.81 Million GBP | 0.0% |
| 2012 Q2 | -1.86 Million GBP | 0.0% |
| 2012 FY | -2.81 Million GBP | -9.1% |
| 2011 Q2 | -3.39 Million GBP | 0.0% |
| 2011 Q4 | -2.58 Million GBP | 0.0% |
| 2011 FY | -2.58 Million GBP | -212.97% |
| 2010 FY | -825 Thousand GBP | 53.88% |
| 2010 Q2 | -1.32 Million GBP | 0.0% |
| 2010 Q4 | -825 Thousand GBP | 0.0% |
| 2009 FY | -1.78 Million GBP | -128.77% |
| 2009 Q4 | -1.78 Million GBP | 0.0% |
| 2009 Q2 | -965 Thousand GBP | 0.0% |
| 2008 Q2 | -1.03 Million GBP | 0.0% |
| 2008 Q4 | -782 Thousand GBP | 0.0% |
| 2008 FY | -782 Thousand GBP | 70.36% |
| 2007 Q4 | -2.63 Million GBP | 0.0% |
| 2007 Q2 | -1.65 Million GBP | 0.0% |
| 2007 FY | -2.63 Million GBP | 3.76% |
| 2006 Q4 | -2.74 Million GBP | 0.0% |
| 2006 FY | -2.74 Million GBP | -51.52% |
| 2006 Q2 | -1.44 Million GBP | 0.0% |
| 2005 Q2 | -2.66 Million GBP | 0.0% |
| 2005 Q4 | -1.8 Million GBP | 0.0% |
| 2005 FY | -1.8 Million GBP | 50.74% |
| 2004 Q2 | -4.3 Million GBP | 0.0% |
| 2004 FY | -3.67 Million GBP | -52.87% |
| 2004 Q4 | -3.67 Million GBP | 0.0% |
| 2003 FY | -2.4 Million GBP | -58.97% |
| 2002 FY | -1.51 Million GBP | 26.04% |
| 2001 FY | -2.04 Million GBP | -962.03% |
| 2000 FY | 237 Thousand GBP | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -1046.086% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 735.494% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 865.512% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 118.027% |
| GB Sciences, Inc. | 1.74 Million USD | 541.488% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 12.735% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -83131.539% |
| Skye Bioscience, Inc. | -5.72 Million USD | -34.831% |
| Zenith Capital Corp. | 10.06 Thousand USD | 76751.252% |
| Agentix Corp. | 37.63 Thousand USD | 20599.54% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 236.574% |
| Biomind Labs Inc. | 711.4 Thousand USD | 1184.363% |
| ContraFect Corporation | -6.02 Million USD | -28.015% |
| CSL Limited | 10.52 Billion USD | 100.073% |
| CytoDyn Inc. | 20.26 Million USD | 138.072% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 2244.556% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 1339.497% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 117.761% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -37699.794% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 931.999% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 1314.512% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -22.359% |
| SQZ Biotechnologies Company | -36.23 Million USD | 78.712% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 996.747% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 148.939% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 444.04% |
| Mesoblast Limited | 55.85 Million USD | 113.81% |
| Marizyme, Inc. | 18.56 Million USD | 141.543% |
| Genus plc | 190.6 Million USD | 104.047% |
| Pharming Group N.V. | 109.8 Million USD | 107.025% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 1234.439% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 767.647% |
| IMV Inc. | 7.67 Million USD | 200.569% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 240.21% |
| MultiCell Technologies, Inc. | 90.04 USD | 8567605.553% |
| ONE Bio Corp. | 9.04 Million USD | 185.334% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 159.587% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 125.248% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 485.826% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 160.236% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 5617.855% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 38929.124% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -4097.326% |
| Enzolytics Inc. | 981.65 Thousand USD | 885.834% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 99.62% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 83.591% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 209.096% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.273% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 287.327% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 2019.672% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 423.306% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 4789.216% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -42012.578% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 445.025% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 5829.53% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -951.01% |
| Helix BioMedix, Inc. | -2.57 Million USD | -200.159% |
| EV Biologics, Inc. | 1.36 Million USD | 663.914% |
| Q BioMed Inc. | 4.06 Million USD | 290.004% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 138.046% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 112.741% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | 4.47 Million USD | 272.499% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 450.329% |
| HST Global, Inc. | 96.79 Thousand USD | 8069.773% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -588768.855% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 3840.808% |
| Halberd Corporation | 144.72 Thousand USD | 5430.382% |
| Resverlogix Corp. | 6.45 Million USD | 219.581% |
| Cell Source, Inc. | 9.23 Million USD | 183.559% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 384.802% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | -5.9 Million USD | -30.678% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 3948.778% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | 2.17 Million USD | 454.111% |
| Kadimastem Ltd | -253.1 Thousand USD | -2947.855% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 5772.651% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 3933.058% |
| LadRx Corporation | -2.03 Million USD | -278.802% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 1314.512% |
| Affymax, Inc. | -5.59 Million USD | -37.827% |
| Itoco Inc. | 228.3 Thousand USD | 3478.893% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 255.622% |
| Mobile Lads Corp. | 484.23 Thousand USD | 1693.076% |
| International Stem Cell Corporation | 2.59 Million USD | 397.845% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | 1.89 Million USD | 506.242% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -1192200.155% |
| Qrons Inc. | 351.42 Thousand USD | 2295.102% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 200.106% |
| SYBLEU INC | 473.71 Thousand USD | 1728.447% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -2990.37% |
| Rebus Holdings, Inc. | 305 Thousand USD | 2629.24% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 273.079% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 12459.896% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 453.716% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 324.641% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 190.193% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 1098.461% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -517.135% |
| Neutra Corp. | 52.18 Thousand USD | 14881.808% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -209.931% |
| PureTech Health plc | -167.19 Million USD | 95.386% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -3049.829% |
| IXICO plc | -4.44 Million USD | -73.564% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 158.357% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 114.064% |
| CSL Limited | 10.52 Billion USD | 100.073% |
| Cellectis S.A. | -43.81 Million USD | 82.395% |